Literature DB >> 16376579

Mutational and functional analyses of xylosyltransferases and their implication in osteoarthritis.

S Schön1, G Huep, C Prante, S Müller, R Christ, F-W Hagena, J Kuhn, K Kleesiek, C Götting.   

Abstract

OBJECTIVE: The hallmark in osteoarthritis (OA) is the loss of proteoglycans (PGs) in articular cartilage (AC). Xylosyltransferase I (XT-I) catalyzes the transfer of xylose to serine residues in the core protein and initiates the biosynthesis of PGs in AC. The XYLT-II gene encodes a highly homologous protein but its biological function is not yet known. Here we investigate for the first time genetic variations in the XYLT-genes and serum XT-I activities and their implication in OA.
METHODS: Denaturing high-performance liquid chromatography (DHPLC) was used for the screening of the XYLT-genes in 49 OA patients. For a detailed characterization of XT-I amino acid exchanges we performed recombinant expression of XT-I mutants in insect cells. Furthermore, the XT activity was measured in the patients' serum.
RESULTS: The variation c.1569C>T (XYLT-II) occurs with a significantly higher frequency in younger OA patients in comparison with the older ones (P<0.001) and the controls (P<0.02). Furthermore, significantly higher serum XT activities were found in patients with a long disease duration of OA (P<0.04). The recombinant XT-I mutants p.P385L and p.I552S had reduced enzymatic activity (85% and 74%) compared with the wildtype (wt).
CONCLUSIONS: Our findings indicate a correlation of the c.1569 T-allele in XYLT-II with an earlier manifestation of OA and that the serum XT activity is a potential biochemical marker for staging and monitoring the progression of AC damage in OA. Comparison of XT-I activity in mutant enzymes in vivo and in vitro revealed that heterozygous mutations are not involved in OA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16376579     DOI: 10.1016/j.joca.2005.11.004

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  13 in total

1.  Serum xylosyltransferase 1 level increases during early posttraumatic osteoarthritis in mice with high bone forming potential.

Authors:  Sarah Y McCoy; Kerry A Falgowski; Padma P Srinivasan; William R Thompson; Erica M Selva; Catherine B Kirn-Safran
Journal:  Bone       Date:  2011-12-02       Impact factor: 4.398

2.  Blood cells transcriptomics as source of potential biomarkers of articular health improvement: effects of oral intake of a rooster combs extract rich in hyaluronic acid.

Authors:  Juana Sánchez; M Luisa Bonet; Jaap Keijer; Evert M van Schothorst; Ingrid Mölller; Carles Chetrit; Daniel Martinez-Puig; Andreu Palou
Journal:  Genes Nutr       Date:  2014-07-15       Impact factor: 5.523

3.  Polymorphisms in the xylosyltransferase genes cause higher serum XT-I activity in patients with pseudoxanthoma elasticum (PXE) and are involved in a severe disease course.

Authors:  S Schön; V Schulz; C Prante; D Hendig; C Szliska; J Kuhn; K Kleesiek; C Götting
Journal:  J Med Genet       Date:  2006-03-29       Impact factor: 6.318

4.  First identification and functional analysis of the human xylosyltransferase II promoter.

Authors:  Benjamin Müller; Christian Prante; Cornelius Knabbe; Knut Kleesiek; Christian Götting
Journal:  Glycoconj J       Date:  2012-08-11       Impact factor: 2.916

5.  N-linked glycan profiling of GGTA1/CMAH knockout pigs identifies new potential carbohydrate xenoantigens.

Authors:  Christopher Burlak; Marshall Bern; Alejandro E Brito; Dragan Isailovic; Zheng-Yu Wang; Jose L Estrada; Ping Li; A Joseph Tector
Journal:  Xenotransplantation       Date:  2013-09-05       Impact factor: 3.907

6.  Xylosyltransferase II is the predominant isoenzyme which is responsible for the steady-state level of xylosyltransferase activity in human serum.

Authors:  Joachim Kuhn; Christian Götting; Brendan J Beahm; Carolyn R Bertozzi; Isabel Faust; Patricia Kuzaj; Cornelius Knabbe; Doris Hendig
Journal:  Biochem Biophys Res Commun       Date:  2015-03-03       Impact factor: 3.575

7.  XT-II, the second isoform of human peptide-O-xylosyltransferase, displays enzymatic activity.

Authors:  Josef Voglmeir; Regina Voglauer; Iain B H Wilson
Journal:  J Biol Chem       Date:  2006-12-28       Impact factor: 5.157

8.  Mutations in fam20b and xylt1 reveal that cartilage matrix controls timing of endochondral ossification by inhibiting chondrocyte maturation.

Authors:  B Frank Eames; Yi-Lin Yan; Mary E Swartz; Daniel S Levic; Ela W Knapik; John H Postlethwait; Charles B Kimmel
Journal:  PLoS Genet       Date:  2011-08-25       Impact factor: 5.917

9.  Human xylosyltransferases--mediators of arthrofibrosis? New pathomechanistic insights into arthrofibrotic remodeling after knee replacement therapy.

Authors:  Isabel Faust; Philipp Traut; Frank Nolting; Jan Petschallies; Elena Neumann; Elke Kunisch; Joachim Kuhn; Cornelius Knabbe; Doris Hendig
Journal:  Sci Rep       Date:  2015-07-28       Impact factor: 4.379

10.  First description of the complete human xylosyltransferase-I promoter region.

Authors:  Isabel Faust; Kai Oliver Böker; Christoph Lichtenberg; Joachim Kuhn; Cornelius Knabbe; Doris Hendig
Journal:  BMC Genet       Date:  2014-12-05       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.